Fridlender et al. showed that TGFβ has the ability to inhibit the anti-tumor activity of TENs [4], thus we reasoned that loss of response to TGFβ by PYMT cells should allow for increased CCL2 production and enhanced anti-tumor activity of TEN at the pre-metastatic site. The gene discussed is TGFB1; the disease is neoplasm.